|
Sudden Death in the Young (SDY) Registry
|
Resource Development
|
CDC, HRSA
|
NINDS, NHLBI
|
The Sudden Death in the Young (SDY) Registry is a surveillance system to track sudden deaths in youths less than or equal to 19 years of age in up to 10 states and gather clinical data and a DNA sample to be used for research to explore the causes and risk factors for sudden death in the young. The SDY Registry is a collaboration between the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and Centers for Disease Control and Prevention (CDC).
|
|
Sudden Unexpected/Unexplained Infant Death (SUID)/Sudden Infant Death Syndrome (SIDS) workgroup
|
Meeting/ Workshop
|
ACF, CDC, FDA, HRSA, IHS
|
NICHD
|
NICHD co-chairs with HRSA, a Federal Sudden Unexpected/Unexplained Infant Death (SUID) /Sudden Infant Death Syndrome (SIDS) Workgroup. The partner agencies include the Administration for Children and Families (ACF); Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH); Food and Drug Administration (FDA); Maternal and Child Health Bureau (MCHB), Health Resources and Services Administration (HRSA); the Indian Health Service (IHS); Division of Information and Education, HHS Office of Minority Health (OMH); Consumer Product Safety Commission (CPSC); and Office of the Deputy Assistant Secretary of Defense, Military and Community Family Policy, Family Advocacy Program, Department of Defense (DoD). The common commitment of the ACF, CDC, NIH, FDA, HRSA, IHS, HHS/OMH, CPSC, and DoD is to address the public health challenges of SIDS and SUID and opportunities for prevention in the United States. The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities. In 2015 proactive and reactive letters were drafted, reviewed and approved by the SUID/SIDS federal workgroup with the intent of encouraging internal and external stakeholders to promote and share safe sleep messages through images and asking people to support safe sleep messages.
|
|
Suicide Mortality Surveillance
|
Other
|
CDC
|
NIMH
|
Through the Suicide Mortality Surveillance project, the Centers for Disease Control (CDC) will develop and refine a rapid suicide mortality surveillance system. Monitoring the trends in cause-specific mortality is critical for identifying emerging public health problems and in generating evidence for health policy development, implementation, and evaluation. Timely information is important for monitoring severity of the disease or condition, allocating resources, and facilitating preventive and control programs. The results from this study will yield valuable information about the validity, feasibility, and timeliness of the enhanced vital statistics system for rapid suicide surveillance.
|
|
Support for Implementation of Agency Public Access Policies
|
Resource Development
|
AHRQ, CDC, FDA, OS
|
NLM
|
NIH Public Access Policy was created by NIH and established in statute by Congress in the Consolidated Appropriations Act 2008, P. L. 110-161, enacted on 12/26/2007. It ensures that the public can access without charge peer-reviewed journal articles arising from NIH-funded research. Since 2008, the PubMed Central (PMC) database has served as the repository for journal articles subject to the NIH Public Access Policy. The Office of Science and Technology Policy (OSTP) coordinated the development of public access policies across federal science agencies, and OSTP released a directive in February 2013 to increase public access to scientific publications and digital data. NIH is collaborating with five divisions and offices in HHS and four agencies outside HHS to use PMC and related services in support of their public access policies. Interagency agreements have been signed with AHRQ, ASPR, CDC, and FDA within HHS, as well as NASA, NIST and VA. Agreements are also being discussed with the Administration for Community Living (ACL) in HHS, and EPA. Researchers from CDC and VA began depositing manuscripts in PMC in early 2015. FDA and NIST, along with the other agencies expect to begin 2016.
|
|
Support for the Federal Interagency Forum on Child and Family Statistics
|
Research Initiative
|
ACF, AHRQ, CDC, HRSA, SAMHSA
|
NICHD, NIDA, NIMH
|
The purpose of this IAA is to provide funds to support the work of the Federal Interagency Forum on Child and Family Statistics (Forum). The purpose of the Forum is to foster collaboration among Federal agencies that produce or use statistical data on children and families. Specifically, the Forum seeks to improve both the quality and use of data on children and families by investigating questions of data quality, data measurement, and data integration; identifying information gaps and data inconsistencies; widening access to information on children and families through the annual publication American’s Children: Key National Indicators of Well-Being and other means; coordinating the development and use of statistical data bases among Federal agencies ; promoting communication among data producers, researchers, and public policymakers; and addressing concerns regarding collection, access, and dissemination of data.
|
|
Surveillance, Epidemiology and End Results (SEER) - Medicare Database
|
Resource Development
|
CMS
|
NCI
|
The Surveillance, Epidemiology, and End Results (SEER)-Medicare data are a unique resource that can be used for research related to the health care provided to persons with cancer. The database results from the linkage of two large population-based data sources: the SEER cancer registries data and the Medicare enrollment and claims files.
|
|
Surveillance, Epidemiology, and End Results (SEER) Program
|
Resource Development
|
CDC
|
NCI
|
The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the U.S. It collects information on incidence, prevalence and survival from specific geographic areas representing 26 percent of the US population. Through SEER, we develop reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in U.S, cancer statistics or cancer surveillance methods.
|
|
Survive and Thrive Global Development Alliance Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NICHD
|
The Survive and Thrive Global Development Alliance aims to reduce maternal, neonatal, and child mortality and promote health in low-resource countries, by increasing access to evidence-based, health interventions, technologies, and training.
|
|
Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT)
|
Resource Development
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NLM
|
This activity provides support for SNOMED CT, a systematically organized computer processable collection of medical terminology covering most areas of clinical information such as diseases, findings, procedures, microorganisms, pharmaceuticals etc. It allows a consistent way to index, store, retrieve, and aggregate clinical data across specialties and sites of care. It also helps organizing the content of medical records, reducing the variability in the way data is captured, encoded and used for clinical care of patients and research.
|
|
Targeting of Interleukin-13 Receptor a2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-ß and PTEN Signaling
|
Research Initiative
|
FDA
|
NIDCR, NIDCD
|
The activity will test new animal models of head and neck squamous cell cancer with targeted treatments using Interleukin-13 Receptor alpha 2 antagonists.
|